What is the price target for CAMP stock?
12 analysts have analysed CAMP and the average price target is 8.93 USD. This implies a price increase of 78.5% is expected in the next year compared to the current price of 5.
NASDAQ:CAMP • US13463J1016
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for CAMP4 THERAPEUTICS CORP (CAMP).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-10-02 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-09-16 | JP Morgan | Downgrade | Overweight -> Neutral |
| 2025-09-15 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2025-05-27 | Wedbush | Initiate | Outperform |
| 2024-11-05 | Leerink Partners | Initiate | Outperform |
| 2024-11-05 | William Blair | Initiate | Outperform |
| 2024-11-05 | JP Morgan | Initiate | Overweight |
| 2024-11-05 | Piper Sandler | Initiate | Overweight |
| 2024-01-11 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-10-09 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-10-06 | Roth MKM | Maintains | Buy -> Buy |
| 2023-10-06 | Craig-Hallum | Downgrade | Buy -> Hold |
| 2023-08-29 | Roth MKM | Reiterate | Buy -> Buy |
| 2023-07-13 | Goldman Sachs | Maintains | Sell -> Sell |
| 2023-07-11 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-06-26 | Jefferies | Downgrade | Buy -> Hold |
| 2023-05-01 | Goldman Sachs | Maintains | Sell |
| 2023-04-28 | Craig-Hallum | Maintains | Buy |
| 2023-04-18 | Goldman Sachs | Maintains | Sell |
| 2022-10-14 | Goldman Sachs | Maintains | Sell |
| 2022-08-16 | Craig-Hallum | Upgrade | Hold -> Buy |
| 2021-12-22 | Canaccord Genuity | Maintains | Buy |
| 2021-12-22 | Craig-Hallum | Downgrade | Buy -> Hold |
| 2021-06-25 | Roth Capital | Maintains | Buy |
| 2021-04-23 | Canaccord Genuity | Maintains | Buy |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 350K | 652K 86.29% | 3.5M 436.81% | 3.302M -5.66% | 4.723M 43.03% | 18.763M 297.27% | 43.064M 129.52% | 82.009M 90.44% | 37.321M -54.49% | 138.9M 272.18% | 245.91M 77.04% | |
| EBITDA YoY % growth | -50.32M -14.04% | -51.3M -1.95% | -50.87M 0.84% | -62.22M -22.31% | -74.46M -19.67% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -52M -15.55% | -53M -1.92% | -52.51M 0.92% | -56.981M -8.51% | -70.3M -23.37% | -73.452M -4.48% | -60.916M 17.07% | -46.867M 23.06% | -106.68M -127.62% | -41.74M 60.87% | 34.474M 182.59% | |
| Operating Margin | -14,857.14% | -8,128.83% | -1,500.29% | -1,725.64% | -1,488.46% | -391.48% | -141.45% | -57.15% | -285.85% | -30.05% | 14.02% | |
| EPS YoY % growth | 1.26 1,700.00% | N/A -591.99% | -2.65 57.25% | -0.94 64.46% | -0.86 8.21% | -0.82 5.22% | -0.63 22.82% | -0.47 26.34% | -0.82 -76.26% | 0.08 109.32% | 0.89 1,060.00% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.21 65.45% | -0.25 59.42% | -0.21 61.67% | -0.20 77.07% |
| Revenue Q2Q % growth | 905.25K 5.51% | 306K -79.56% | -100.00% | -100.00% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -12.727M 2.10% | -15.72M -20.92% | -16.194M -19.87% | -17.13M -31.77% |
All data in USD
12 analysts have analysed CAMP and the average price target is 8.93 USD. This implies a price increase of 78.5% is expected in the next year compared to the current price of 5.
CAMP4 THERAPEUTICS CORP (CAMP) will report earnings on 2026-05-11.
The consensus EPS estimate for the next earnings of CAMP4 THERAPEUTICS CORP (CAMP) is -0.21 USD and the consensus revenue estimate is 905.25K USD.
The consensus rating for CAMP4 THERAPEUTICS CORP (CAMP) is 85 / 100 . This indicates that analysts generally have a positive outlook on the stock.